A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Record History

See every version on ClinicalTrials.gov ↗

1. Notable Sep 24, 2026 Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC

   • Trial sites expanded: 144 → 150 locations
   • Eligibility criteria expanded, about 12 words
   • Secondary endpoints: details revised at 14 of 24 entries
2. Minor Aug 27, 2026 Trial sites expanded: 124 → 144 locationsv12
3. Minor Jul 30, 2026 Trial sites expanded: 109 → 124 locationsv11
4. Notable Jul 15, 2026 Primary endpoint(s) modified

   • Trial sites expanded: 103 → 109 locations
   • Eligibility criteria shortened, about 17 words
   • Secondary endpoints revised (24)

   v10
5. Minor Jul 2, 2026 Trial sites expanded: 65 → 103 locationsv9
6. Minor Jun 4, 2026 Trial sites expanded: 43 → 65 locationsv8
7. Minor May 7, 2026 Trial sites expanded: 39 → 43 locationsv7
8. Minor Apr 9, 2026 Trial sites expanded: 33 → 39 locationsv6
9. Minor Mar 18, 2026 Study sites: 10 to 33v5
10. Minor Feb 12, 2026 Study sites: 9 to 10v4
11. Notable Feb 9, 2026 Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less

    • Study sites: 0 to 9
    • Start date changed from estimate of Feb 20, 2026 to Feb 4, 2026
    • Secondary endpoints: details revised at 1 of 24 entries
    • Eligibility criteria expanded, about 1 word
12. Minor Dec 4, 2025 Re-verified, no change to tracked fieldsv2
13. Minor Nov 21, 2025 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.